Terms: = Uterine cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Prognosis
125 results:
1. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
[TBL] [Abstract] [Full Text] [Related]
2. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
[TBL] [Abstract] [Full Text] [Related]
3. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
[TBL] [Abstract] [Full Text] [Related]
4. prognosis of polymerase epsilon (pole) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
[TBL] [Abstract] [Full Text] [Related]
5. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract] [Full Text] [Related]
6. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for pole Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
[TBL] [Abstract] [Full Text] [Related]
8. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
[TBL] [Abstract] [Full Text] [Related]
9. Validation of Modaplex pole mutation assay in endometrial carcinoma.
Dorca E; Velasco A; Varela M; Gatius S; Villatoro S; Fullana N; Cuevas D; Vaquero M; Birnbaum A; Neumann K; Matias-Guiu X
Virchows Arch; 2023 Dec; 483(6):787-794. PubMed ID: 37874375
[TBL] [Abstract] [Full Text] [Related]
10. Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics.
Liwei L; He L; Yibo D; Luyang Z; Zhihui S; Nan K; Danhua S; Junzhu W; Zhiqi W; Jianliu W
World J Surg Oncol; 2023 Oct; 21(1):332. PubMed ID: 37865800
[TBL] [Abstract] [Full Text] [Related]
11. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
13. Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis.
Luzarraga Aznar A; Bebia V; López-Gil C; Giraldo A; Montoya MP; Verges R; Jauregui A; Castellvi J; Pérez-Benavente A; Colás E; Gil-Moreno A; Cabrera S
Int J Gynecol Cancer; 2023 Oct; 33(10):1564-1571. PubMed ID: 37726197
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract] [Full Text] [Related]
15. A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters.
Wang W; Li X; Gao Y; Zheng H; Gao M
BMC Cancer; 2023 Aug; 23(1):720. PubMed ID: 37528420
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancer.
Pelegrina B; Paytubi S; Marin F; Martínez JM; Carmona Á; Frias-Gomez J; Peremiquel-Trillas P; Dorca E; Zanca A; López-Querol M; Onieva I; Benavente Y; Barahona M; Fernandez-Gonzalez S; De Francisco J; Caño V; Vidal A; Pijuan L; Canet-Hermida J; Dueñas N; Brunet J; Pineda M; Matias-Guiu X; Ponce J; Bosch FX; De Sanjosé S; Alemany L; Costas L
EBioMedicine; 2023 Aug; 94():104716. PubMed ID: 37480623
[TBL] [Abstract] [Full Text] [Related]
17. Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma.
Moreira I; Ferreira M; Garcia S; Novais P; Gama J; Ferro B; Leite-Silva P; Frutuoso C; Pires M; Barbosa A; Pinto C; Teixeira MR; Pereira D; Bartosch C
Gynecol Oncol; 2023 Sep; 176():53-61. PubMed ID: 37453219
[TBL] [Abstract] [Full Text] [Related]
18. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas.
Pain FA; Beinse G; Azaïs H; Auvray-Kuentz M; Garcin LM; Delanoy N; Bentivegna E; Benoit L; Nguyen-Xuan HT; Blons H; Fabiano E; LE Frère Belda MA; Bats AS; Koual M
Eur J Surg Oncol; 2023 Sep; 49(9):106954. PubMed ID: 37349159
[TBL] [Abstract] [Full Text] [Related]
19. A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
Zheng S; Wu Y; Donnelly ED; Strauss JB
Gynecol Oncol; 2023 Aug; 175():97-106. PubMed ID: 37336081
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract] [Full Text] [Related]
[Next]